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The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2)
is a key regulator of carbohydrate metabolism in liver. The goal of this study was to elucidate the
regulatory role of Ser-32 phosphorylation on the kinase domain mediated dimerization of PFK-2/
FBPase-2. Fluorescence-based mammalian two-hybrid and sensitized emission ﬂuorescence reso-
nance energy transfer analyses in cells revealed preferential binding within homodimers in contrast
to heterodimers. Using isolated proteins a close proximity of two PFK-2/FBPase-2 monomers was
only detectable in the phosphorylated enzyme dimer. Thus, a ﬂexible kinase interaction mode exists,
suggesting dimer conformation mediated coupling of hormonal and posttranslational enzyme reg-
ulation to the metabolic response in liver.
Structured summary of protein interactions:
PFK-2/FBPase-2 physically interacts with PFK-2/FBPase-2 by ﬂuorescent resonance energy transfer (View
Interaction: 1, 2)
PFK-2/FBPase-2 physically interacts with PFK-2/FBPase-2 by two hybrid (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction regulatory metabolite of the mammalian carbohydrate metabolismFour genes, designated PFKFB1-PFKFB4, encode themammalian 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-
2) isoenzymes, and differential splicing gives rise to a number of
isoforms that share the catalytic core of the parent isoenzyme, but
differ in ﬂanking sequences [1]. The N-terminal kinase (EC
2.7.1.105) of PFK-2/FBPase-2 synthesizes fructose 2,6-bisphosphate
from fructose 6-phosphate and ATP, whereas the C-terminal bis-
phosphatase (EC 3.1.3.46) of PFK-2/FBPase-2 catalyzes the hydroly-
sis of fructose 2,6-bisphosphate to fructose 6-phosphate and
inorganic phosphate. As neither the kinase reaction nor the bisphos-
phatase reaction is freely reversible the steady state concentration
of fructose 2,6-bisphosphate is determined by the kinase:bisphos-
phatase activity ratio [2]. Fructose 2,6-bisphosphate is an importantchemical Societies. Published by E
domain; DMEM, Dulbecco’s
ﬂuorescent protein; EYFP,
ce resonance energy transfer;
,6-bisphosphatase
Biochemistry and Molecular
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k.de (S. Baltrusch).that has been found in virtually every eukaryotic tissue or cell [3].
The complex regulation of PFK-2/FBPase-2 through metabolic
and hormonal signals is best understood in the case of the liver iso-
enzyme which is encoded by the PFKFB1 gene and is the predom-
inant PFK-2/FBPase-2 expressed in the liver and kidney [2,4]. The
PFK-2/FBPase-2 protein exists as a dimer that is stabilized by
protein–protein interactions between the kinase domains [5,6].
The hepatic PFK-2/FBPase-2 is posttranslationally regulated by
cAMP-dependent phosphorylation by protein kinase A in response
to glucagon at the amino acid residue Ser-32 [7,8]. Phosphorylation
of Ser-32 causes both a reduction of the kinase activity and an
enhancement of the bisphosphatase activity resulting in a decrease
in the kinase:bisphosphatase activity ratio and subsequently in in-
creased hepatic glucose production, consistent with the fasting
state [2]. Molecular rearrangements in the PFK-2/FBPase-2 dimer
have been shown to be involved in the regulation of the enzyme
activities of the kinase and the bisphosphatase [9–11].
In liver the glucose phosphorylating and glucose-sensing
enzyme glucokinase (Hexokinase Type IV; EC 2.7.1.1) has an
important role in regulating fuel metabolism. A regulatory nexus
between glucokinase and PFK-2/FBPase-2 by two different
mechanisms has been conclusively demonstrated. First, a rise inlsevier B.V. All rights reserved.
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sion of glucokinase [12]; second, the posttranslational regulation
of PFK-2/FBPase-2 binding to, and activating, glucokinase [13–16].
In the present study the effect of cAMP-dependent Ser-32
phosphorylation on homodimerization of the rat liver PFK-2/
FBPase-2 enzyme was investigated. The interaction between two
PFK-2/FBPase-2 monomers was analyzed by a mammalian two-hy-
brid system and ﬂuorescence resonance energy transfer (FRET) for
the liver wild-type enzyme and compared to a Ser-32 phosphoryla-
tion deﬁcient S32A/H258Amutant [7,8] of the bifunctional enzyme.
2. Materials and methods
2.1. Cell culture and transfection
COS cells were grown in DMEM supplemented with 25 mmol/l
glucose, 10% (v/v) fetal calf serum, 10 U/ml penicillin, 10 lg/ml
streptomycin and 2 mmol/l glutamine in a humidiﬁed atmosphere
at 37 C and 5% CO2. Cells were transfected with jetPEI (Qbiogene,
Montreal, QC, Canada) according to manufacturer’s instructions.
2.2. Mammalian two-hybrid analysis
The cDNAs of rat liver PFK-2/FBPase-2 wild-type and S32A/
H258A mutant were ampliﬁed by PCR and subcloned in frame (SalIFig. 1. Effect of forskolin on cAMP content and Ser-32 phosphorylation of PFK-2/FBPase-2
content was measured by a luminometric assay (A). The phosphorylated cellular prote
Finally the amount of phosphorylated PFK-2/FBPase-2 was determined by Western blot
The amount of Ser-32 phosphorylation was determined using a speciﬁc antibody agains
PFK-2/FBPase-2 (PFK2) wild-type (WT) or S32A/H258A mutant (Mut). The amount of S
representative blot is shown (E). Immunoblot bands were quantiﬁed (F). Data are expre
three (B, D) individual experiments. ⁄, P < 0.05; ⁄⁄, P < 0.01 (Student’s t-test).and HindIII restriction sites) to both the GAL4-DNA-BD into pM and
the VP16-AD into pVP16 (Clontech, Palo Alto, CA). The ﬂuores-
cence-based reporter plasmid pHASH-3 [17] was used in combina-
tion with the pM and pVP16 constructs as described [18]. COS
cells were seeded in six-well microplates at a density of 2 104 cells
and grown for one day. For each transfection 0.4 pmol of the reporter
vector pHASH-3 was used in combination with 0.1 pmol of the
expression vector pM (negative control), pM–PFK-2/FBPase-2 wild-
type, or pM–PFK-2/FBPase-2(S32A/H258A) and 0.1 pmol of the
expression vector pVP16 (negative control), pVP16–PFK-2/FBPase-2
wild-type, or pVP16–PFK-2/FBPase-2(S32A/H258A). After incubation
for 20 h the cells were incubated for further 2 h in DMEM with
or without 10 lmol/l forskolin (ICN Biomedicals (Irvine, CA,
USA). Thereafter analysis was performed as described previously
[18].
2.3. Determination of cAMP
COS cells were incubated for 15 min in Krebs–Ringer solution
with or without 100 lmol/l forskolin. Analysis of cAMP was
performed with the cAMP-GloTM Assay (Promega, Mannheim,
Germany) according to manufacturer’s instructions. Light emission
was recorded as a 1-s integral using a Victor2 Multilabel Counter
(Wallac, Freiburg, Germany). cAMP values were calculated in rela-
tion to cAMP standard values.. COS cells were incubated in the absence or presence of forskolin. The cellular cAMP
in fraction was separated from the unphosphorylated by afﬁnity chromatography.
analysis. A representative blot is shown (B). Immunoblot bands were quantiﬁed (C).
t phospho-Ser-32-PFK-2/FBPase-2 (D). COS cells were transfected with pcDNA3zeo-
er-32 phosphorylated PFK-2/FBPase-2 was determined by Western blot analysis. A
ssed as percentage of untreated cells. Shown are means ± SEM from four (A, F) and
Fig. 2. Effect of Ser-32 phosphorylation on dimerization strength of PFK-2/FBPase-2
wild-type and S32A/H258A mutant two-hybrid fusion proteins in COS cells. The
interaction strength of the fusion proteins DNA-BD-PFK-2/FBPase-2 and AD-PFK-2/
FBPase-2 was measured in a ﬂuorescence-based mammalian two-hybrid assay for
wild-type enzyme (A) and for S32A/H258A mutant (B). DNA-BD and AD (white
bars), DNA-BD-PFK-2/FBPase-2 and AD (striped bars), DNA-BD and AD-PFK-2/
FBPase-2 (checked bars) or DNA-BD-PFK-2/FBPase-2 and AD-PFK-2/FBPase-2 (black
bars) were overexpressed in COS cells and preincubated with or without forskolin.
Data are expressed as means ± SEM from three individual experiments with a total
of 82 to 379 nuclei analyzed. ⁄⁄⁄, P < 0.001 compared with negative controls;
##, P < 0.01 compared to the respective cells not treated with forskolin (ANOVA/
Bonferroni’s test).
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The cDNA encoding rat liver PFK-2/FBPase-2 wild-type or S32A/
H258A mutant or human beta-cell glucokinase was ampliﬁed by
PCR and subcloned in frame (KpnI and BamHI or ApaI and BamHI
restriction sites, respectively) to the Dendra2 into pDendra2-C
(Evrogen, Moscow, Russia) [19]. COS cells were seeded at a density
of 3  105 cells on 35-mm glass-bottom dishes (MatTek, Ashland,
MA) and transfected one day later. After 48 h cells were incubated
for 2 h with or without 10 lmol/l forskolin. Thereafter analysis was
performed with a cellR/Olympus IX81 inverted microscope system
and an UPLSAPO 60 1.35 numerical aperture oil-immersion
objective (Olympus, Hamburg, Germany). D482/18 and HQ561/14
excitation ﬁlter were used for green Dendra2 and red Dendra2,
respectively (AHF Analysentechnik, Tübingen, Germany). For FRET
analyses Dendra2 and red Dendra2 emission were detected simul-
taneously using a DV-CC Dual View Simultaneous Imaging System
(Optical Insights, LLC, Tucson, AZ) equipped with a 565 dcxr beam
splitter and D514/30 and HQ617/73 emission ﬁlters. The sensitized
emission-based FRET efﬁciency (FRETN) was calculated before and
after photoconversion for 5 s with a 405 nm laser diode from the
green Dendra2 emission with excitation at 482 nm, red Dendra2
emission with excitation at 482 nm, and red Dendra2 emission
with excitation at 561 nm, based on the calculation of Vanderklish
et al. [20].
pDendra2–GK, pDendra2–PFK-2/FBPase-2 and pDendra2–PFK-
2/FBPase-2–S32A/H258A protein, respectively was isolated from
COS cells using Dynabeads Protein G (Invitrogen, Karlsruhe,
Germany) with anti-Dendra2-IgG antibody (Evrogen) at 4 C
according to manufacturer’s instructions. One fraction of each
preparation was immediately used for FRET measurements. The
remaining fraction was incubated at 20 C for at least 24 h before
the measurement was performed. The red Dendra2 (ﬁlter setup
F572/28, AHF Analysentechnik) of 0.2 lmol/l puriﬁed protein in
100 ll 20 mmol/l Tris, 100 mmol/l NaCl and 2 mmol/l dithiothrei-
tol (pH 7.4) was recorded in a black microplate as a 0.1-s integral
in a Victor2 Multilabel Counter (Wallac, Freiburg, Germany) while
the green Dendra2 was excited (ﬁlter setup F485/14, AHF Analy-
sentechnik). Then the sample was irradiated with a 405 nm UV
diode at 12 V for 15 min to induce photoconversion of Dendra2
and the ﬂuorescence measurement was repeated. The increase of
red ﬂuorescence with F485/14 excitation after photoconversion
was calculated.
2.5. Western blot analysis
Phosphorylated proteins were isolated from COS cells in the
presence of phosphatase inhibitors according to the instructions
of the PhosphoProtein Puriﬁcation handbook (Qiagen, Hilden,
Germany) and fractionated by reducing 10% SDS-PAGE and electro-
blotted to polyvinylidine diﬂuoride membranes. The speciﬁc
protein bands were visualized using a rat liver FBPase-2 antibody
raised in chicken [15] and the appropriate IRDye secondary
antibody (Licor Biosciences, Lincoln, NE, USA) in the Licor Infrared
Imaging System. Cells were transfected with 5 lg of the pDendra2–
PFK-2/FBPase-2 wild-type or S32A/H258A mutant, or pcDNA3zeo–
PFK-2/FBPase-2 wild-type or S32A/H258A mutant [15] and
cultured for one further day. Homogenized cellular protein was
fractionated by reducing 10% SDS-PAGE and electroblotted to
polyvinylidine diﬂuoride membranes. PFK-2/FBPase-2 and Den-
dra2–PFK-2/FBPase-2 (40 lg total cellular protein) analyses were
performed using the chicken FBPase-2 antibody [15] and an anti-
Dendra2-IgG antibody (Evrogen), respectively, and the appropriate
IRDye secondary antibodies (Licor Biosciences) in the Licor Infrared
Imaging System. Phospho-Ser-32-PFK-2 analyses (150 lg total cel-
lular protein) were performed using a phospho-speciﬁc antibodyraised against the peptide LQRRRG[p]SSIPQF (Eurogentec, Seraing,
Belgium) and the enhanced chemiluminescence detection system
(GE Healthcare, Amersham, Buckinghamshire, UK) in the ChemiLux
Imager (Intas, Göttingen, Germany).
2.6. Statistical analyses
Statistical analyses were performed using the Prism analysis
program (GraphPad, San Diego, CA, USA).
3. Results
3.1. Effect of forskolin on Ser-32 phosphorylation of PFK-2/FBPase-2 in
COS cells
PFK-2/FBPase-2 is endogenously expressed in COS cells (Fig. 1).
To investigate phosphorylation of the liver-type PFK-2/FBPase-2
COS cells were treated with forskolin mimicking the effect of
glucagon in the liver. Forskolin induced a 60% increase of the cAMP
content (Fig. 1A), a 65% increase in phosphorylated PFK-2/FBPase-2
(Fig. 1B and C), and a 40% increase in Ser-32 phosphorylated PFK-2/
FBPase-2 (Fig. 1D) in COS cells. Overexpression of the liver wild-
type PFK-2/FBPase-2 and the S32A/H258A mutant under control
of the CMV promoter resulted in a comparable expression level
(data not shown). The liver wild-type enzyme showed phospho-
Fig. 3. Model of the binding behavior of endogenous PFK-2/FBPase-2 and themutant PFK-2/FBPase-2mammalian two-hybrid fusion proteins. The endogenous PFK-2/FBPase-2
is depicted in light gray. The PFK-2/FBPase-2 S32A/H258Amutant fused to the indicated two-hybrid domains (DNA-BD and AD, respectively) is shown in dark gray. The kinase
and bisphosphatase domains of PFK-2/FBPase-2 are designated as K and B, respectively. The letter size represents the activity status of the domain. Phospho-Ser-32 residues are
indicated as gray circles.
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signiﬁcantly increased by forskolin treatment, but not the S32A/
H258A mutant PFK-2/FBPase-2 (Fig. 1E and F).
3.2. Mammalian two-hybrid interaction within the liver PFK-2/
FBPase-2 protein homodimer
A recently established ﬂuorescence-based mammalian two-
hybrid system [18] was used to study the effect of phosphorylation
on PFK-2/FBPase-2 dimerization in COS cells. The expression level
of the two hybrid PFK-2/FBPase-2 fusion proteins was comparable
to the endogenous PFK-2/FBPase-2 (data not shown). The interac-
tion strength of the fusion proteins DNA-BD-PFK-2/FBPase-2 and
AD-PFK-2/FBPase-2 was measured for the liver wild-type enzyme
(Fig. 2A) and for the S32A/H258A mutant (Fig. 2B). Signiﬁcant
dimerization of both, the wild-type and the mutant enzyme could
be demonstrated. The EYFP/ECFP ratio in untreated cells was six
times higher than in the negative controls for the wild-type
PFK-2/FBPase-2 and eight times higher than in the negative controls
for the mutant enzyme. When the cells were incubated for 2 h in
the presence of forskolin, the two-hybrid signal was unchanged
for the wild-type enzyme. In case of the S32A/H258A mutant for-
skolin treatment resulted in an almost 50% increase of the EYFP/
ECFP ratio. Because the liver-type PFK-2/FBPase-2 is endogenously
expressed in COS cells (Fig. 1) this can be explained by an intramo-
lecular quenching effect on the two-hybrid fusion proteins (Fig. 3).
3.3. Interaction of PFK-2/FBPase-2 kinase domains within the enzyme
homodimer
Dendra2 is a green-to-red photoconvertible ﬂuorescent protein.
The UV light-induced red ﬂuorescence of Dendra2 is stable [19,21].
Thus, the two ﬂuorescent states can act as a donor–acceptor pair in
FRET experiments, and Dendra2 can be used to detect close spatial
proximities of the protein dimers fused to it in vivo and in vitro.
The direct interaction of the Dendra2 fusion proteins was mea-
sured in COS cells using FRETN for the liver wild-type enzyme and
for the S32A/H258A mutant with or without forskolin after photo-
conversion (Fig. 4A). The background value was determined bymeasurement of FRETN in the same cells before photoconversion.
Consistent with the mammalian two-hybrid results a signiﬁcant
dimerization was determined for both, the PFK-2/FBPase-2 wild-
type and S32A/H258A mutant (Fig. 4A). FRETN in untreated cells
was 156% higher than in the negative controls for the wild-type
PFK-2/FBPase-2 and 148% higher than in the negative controls for
the mutant enzyme. Conﬁrming our observation using the mam-
malian two-hybrid analysis, forskolin treatment for 2 h resulted
only in case of the S32A/H258A mutant in a further signiﬁcant in-
crease in FRETN of almost 100%. Fluorescence images and Western
blot analyses conﬁrmed comparable overexpression of the PFK-2/
FBPase-2 wild-type and S32A/H258A mutant as well as similar
proteins levels with respect to the endogenous PFK-2/FBPase-2
(Fig. 4B–E).
To avoid the quenchingby endogenous PFK-2/FBPase-2, Dendra2
fusion proteins of the liver wild-type enzyme and the S32A/H258A
mutant were isolated from COS cells before FRET analysis. Glucoki-
nase a monomeric protein [22] with a comparable size as PFK-2/
FBPase-2 was used as a Dendra2 fusion protein in control experi-
ments to determine the amount of bleed-through of green light that
is detected by the red emission channel due to unavoidable trans-
mission of the ﬂuorescence ﬁlter (80.3 ± 9.4 cps). A signiﬁcant FRET
signal was detected between wild-type PFK-2/FBPase-2 proteins
immediately used after isolation (253.4 ± 29.0 cps), but only a min-
or signal between S32A/H258A mutant proteins (113.4 ± 34.4 cps)
(Fig. 5). To demonstrate speciﬁcity of the FRET signal, proteins from
batches previously freshly measured were incubated at 20 C.
Incubation at20 C generally diminishes protein phosphorylation,
and thus phosphate binding at Ser-32 of PFK-2/FBPase-2. Nearly no
FRET signal was observed after incubation at 20 C for the wild-
type (101.3 ± 34.3 cps) and mutant (102.6 ± 33.8 cps) PFK-2/
FBPase-2 proteins (Fig. 5). This provides clear evidence that phos-
phorylation leads to a stronger binding of the PFK-2/FBPase-2 ki-
nase domains within the enzyme homodimer (Fig. 6).
4. Discussion
Glucagon, secreted from pancreatic alpha cells in case of hypo-
glycemia, is an important regulator of the liver PFK-2/FBPase-2
Fig. 4. Analysis of interaction of PFK-2/FBPase-2 kinase domains within the enzyme
homodimer in COS cells Fusion proteins of the green-to-red photoconvertible
ﬂuorescent protein Dendra2 and the liver PFK-2/FBPase-2 wild-type (A (white and
black bars), B and D) or the S32A/H258A mutant (A (striped and gray bars), C and E)
were expressed in COS cells. Measurements of FRET were performed before (A,
white and striped bars) and after (A, black and gray bars) converting a deﬁned
fraction of green Dendra2 to red Dendra2. Data are expressed as means ± SEM from
six individual analyses (A). ⁄, P < 0.05 compared to analysis in the same cells before
photoconversion; ###, P < 0.001 compared to the respective cells not treated with
forskolin (ANOVA/Bonferroni’s test). Representative images of transfected cells are
shown (B and C). Scale bar 5 lm. For analysis of expressed fusion proteins a
Dendra2 antibody (left blot) and for both, endogenous and expressed fusion
proteins a speciﬁc antibody against FBPase-2 (right blot) was used. Shown are
representative blots from two individual experiments (D and E).
Fig. 5. Analysis of interaction of isolated PFK-2/FBPase-2 kinase domains within the
enzyme homodimer fusion proteins of the green-to-red photoconvertible ﬂuores-
cent protein Dendra2 and the liver PFK-2/FBPase-2 wild-type (black bars), the
S32A/H258A mutant (gray bars), or the enzyme glucokinase (white bars) were
expressed in COS cells and puriﬁed. Measurements of FRET were performed before
and after converting a deﬁned fraction of green Dendra2 to red Dendra2. The
increase in FRET is shown for proteins immediately used after puriﬁcation and for
proteins from the same puriﬁcation batch but incubated at 20 C before the
measurement (gray background). Data are expressed as means ± SEM from three
individual experiments. ⁄, P < 0.05 compared to Dendra2-GK; #, P < 0.05 compared
to freshly puriﬁed Dendra2–PFK-2/FBPase-2 mutant; §, P < 0.05 compared to
Dendra2–PFK-2/FBPase-2 wild-type incubated at20 C (ANOVA/Bonferroni’s test).
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causes phosphorylation of PFK-2/FBPase-2 on Ser-32 and thereby
activation of the bisphosphatase [7,8,23]. The resulting low fructose
2,6-bisphosphate concentration is imperative for the net produc-
tion of glucose from the liver by glycogen breakdown and during
longer fasting by gluconeogenesis [2,16,24]. Certainly, this process
can be rapidly counteracted by insulin, secreted from pancreatic
beta cells in case of hyperglycemia, which provokes cAMP degrada-
tion and thereby Ser-32 dephosphorylation of PFK-2/FBPase-2 [24].
The resulting fast switch to a high kinase activity assures effective
activation of 6-phosphofructo-1-kinase by fructose 2,6-bisphos-
phate, thus, glycolysis upon hepatic glucose uptake [7,8,23].
While it has been shown by the yeast two-hybrid system that
dimerization of the bifunctional enzyme is mediated by the
N-terminal kinase domain [5], the role of Ser-32 phosphorylation
on enzyme dimerization is so far poorly understood. Implementing
the two-hybrid assays in mammalian cells paves the way to studythe effect of physiologically relevant posttranslational modiﬁca-
tions on protein interactions [18].
However, certain aspects should be taken into account inter-
preting the mammalian two-hybrid data. First, the quantiﬁcation
of a dimerization via a two-hybrid signal will always lead to an
underestimation of the binding strength. Two monomers fused to
the same two-hybrid domain can dimerize, namely two AD or
two DNA-BD fusion proteins. In this case, even though there is
an interaction between the proteins the complex does not induce
the reporter protein. Second, the PFK-2/FBPase-2 enzyme is
expressed in COS cells. Thus, interaction of the two-hybrid fusion
proteins with endogenous PFK-2/FBPase-2 will further reduce the
signal for the dimerization.
The present study allows the conclusion that a dephosphorylated
endogenous PFK-2/FBPase-2 monomer could bind to every dephos-
phorylated exogenous monomer, irrespective of the S32Amutation
in the two-hybrid fusion protein. Dephosphorylation of Ser-32 prior
to addition of forskolin, mimicking in this study the effect of gluca-
gon in the liver, is assured by the presence of glucose in media [7].
This results in ‘‘mixed dimer’’ formation with regard to the Ser-32
phosphorylation state, as indicated with a circle in the scheme
(Fig. 3). ‘‘Mixed dimers’’ clearly exert a quenching effect on the
two-hybrid signal because the involved two-hybrid fusion proteins
do not contribute to the induction of the reporter gene. It can be as-
sumed that such a formation of a dimer comprised of different iso-
zyme monomers is unfavorable because the monomers may exist
in different activity states, partially negating the ability of the dimer
to fully switch upon phosphorylation or dephosphorylation.
As shown by Western blot analyses and depicted in the scheme
(Fig. 3) forskolin treatment increased Ser-32 phosphorylation
within the endogenous PFK-2/FBPase-2 pool and within the wild-
type PFK-2/FBPase-2 two-hybrid fusion protein pool, but not in
the S32A/H258A mutant PFK-2/FBPase-2 two-hybrid fusion pro-
tein pool. Only in the case of the S32A/H258A mutant PFK-2/
FBPase-2 approach, therefore, more two-hybrid fusion proteins
were able to augment reporter gene expression. These results sup-
port the hypothesis that at high cAMP concentrations, PFK-2/
FBPase-2 dimers preferentially sort with regard to the Ser-32 phos-
phorylation state. This is important for the liver-type enzyme
because a dimer comprised of dephospho- and phospho-Ser-32
Fig. 6. Scheme of FRET within a dimer of Dendra2–PFK-2/FBPase-2 wild-type. PFK-2/FBPase-2 is depicted in light gray, the kinase and bisphosphatase domains are designated
as K and B, respectively. The letter size represents the activity status of the domain. Green Dendra2 is shown as a fading globe with white center. Red Dendra2 is shown as a
fading globe with dark center. Phosphorylation of Ser-32 is indicated by gray circles. The dashed arrow indicates radiationless transfer of excitation energy from the donor
(green Dendra2) to the acceptor (red Dendra2).
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ratio, and thereby leave cellular fructose 2,6-bisphosphate content
unchanged. In contrast, the PFK-2/FBPase-2 wild-type enzyme in
the two-hybrid fusion protein would not be distinguishable from
the endogenous enzyme with respect to the phosphorylation state.
Therefore, ‘‘mixed dimers’’ would form to the same extent before
and after forskolin treatment, exactly as observed in the mamma-
lian two-hybrid experiments.
The preferential homodimerization of PFK-2/FBPase-2 with
regard to the phosphorylation state could be conﬁrmed by FRET.
By this technique direct interaction between proteins can be mea-
sured in living cells and using isolated proteins. FRETN analysis
was performed using the photoconvertible ﬂuorescent protein
Dendra2 fused to the N-terminus of the PFK-2/FBPase-2 wild-type
or S32A/H258A mutant enzyme. While green Dendra2 being the
FRET donor, the FRET acceptor, namely the red ﬂuorescent form,
was produced by restricted UV light exposure. In COS cells in the
presence of forskolin with enhanced Ser-32 phosphorylation of
endogenous PFK-2/FBPase-2 the lowest quenching on the FRETN
signal was determined in case of overexpression of the S32A/
H258A mutant PFK-2/FBPase-2.
Direct evidence for the strengthening of PFK-2/FBPase-2 dimer-
ization by Ser-32 phosphorylationwas obtained using isolated Den-
dra2 proteins in an artiﬁcial system. FRET was detectable mainly in
the phosphorylatedwild-type enzyme fusion protein. Loss of Ser-32
phosphorylation reduced the FRET signal, providing clear evidence
for a stronger interaction of the monomers in the phosphorylated
state. Together our data revealed a higher binding strength within
the Ser-32-phosphorylated PFK-2/FBPase-2 dimer. Phosphorylation
of Ser-32 inhibits the PFK-2 activity and activates FBPase-2.
Activity modulation of PFK-2/FBPase-2 is mediated by the 22
amino acids in the N-terminus and the 30 amino acids in the
C-terminus [9,10] by a poorly understood mechanism. The crystal
structure indicates that the kinase domains form a continuous
b-sheet structure across the dimer interface. The ‘‘tightening’’ of
the quaternary structure observed upon phosphorylation of Ser-
32 suggests either increased interaction between the kinase
domains, closer association of FBPase-2 domains, or both. The
latter is consistent with the proposed molecular mechanism for
activation of FBPase-2 by Ser-32 phosphorylation [25]. The gluco-
kinase-binding site is located in the FBPase-2 domain [5]. Thus, aconformational change in the quaternary structure indicated
by the present study suggests that in phospho-Ser-32-PFK-2/
FBPase-2 the glucokinase-binding site in the FBPase-2 domains of
the dimer may preclude binding of glucokinase.
The results strengthen the proposed molecular coordination of
hepatic carbohydrate metabolism by PFK-2/FBPase-2 and the glu-
cose-sensor enzyme glucokinase. In previous studies it was shown
that glucokinase enzyme activity is increased upon co-overexpres-
sion of the PFK-2/FBPase-2 liver isoenzyme [15]. Furthermore
glucokinase activation through the interaction with the liver
wild-type PFK-2/FBPase-2, but not the S32A/H258A mutant PFK-
2/FBPase-2, could be counteracted by forskolin indicating binding
of glucokinase mainly to the dephosphorylated PFK-2/FBPase-2
[15]. In hepatocytes only the S32A/H258A mutated bifunctional
enzyme was able to counteract the glucagon-induced reduction
of the cellular fructose 2,6-bisphosphate concentration, inhibition
of glycolysis and reduction of the freely diffusible glucokinase frac-
tion [26]. Interestingly, with recombinant puriﬁed proteins it could
be demonstrated that glucokinase:PFK-2/FBPase-2 complex forma-
tion increases both the glucokinase and the PFK-2 activity whereas
FBP-2 activity remains unchanged [16]. Therefore a rise of glucose
in liver not only increases the glucokinase enzyme activity and the
kinase:bisphosphatase activity ratio but in addition activates
both enzymes by promoting formation of a glucokinase2(PFK-2/
FBPase-2)2 complex [16]. The sorting of PFK-2/FBP-ase-2 mono-
mers according to Ser-32 phosphorylation state observed here con-
tributes to the bioswitching mechanisms of the bifunctional
enzyme because it assures that both monomers in the dimer are
in the same activity state (kinase:bisphosphatase ratio) and gluco-
kinase-binding state.
The present study provides new knowledge upon dimerization
of the bifunctional enzyme PFK-2/FBPase-2. The results revealed
a novel aspect of the bifunctional enzyme’s quaternary structure,
namely that the dimer favors binding of monomers in the same
Ser-32 phosphorylation state in living cells. It appears that phos-
phorylation at Ser-32 tightens the liver PFK-2/FBPase-2 dimer
complex. This supports the understanding of the mechanisms of
interaction between PFK-2/FBPase-2 and the glucose-sensor
enzyme glucokinase, which is crucially important for the coordi-
nated regulation of glucose phosphorylation and the committing
step of glycolysis in liver.
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